Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2019; 25(32): 4580-4597
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4580
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4580
Chronic hepatitis delta: A state-of-the-art review and new therapies
Christy Gilman, Theo Heller, Christopher Koh, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, United States
Author contributions: All authors contributed equally to this manuscript in regard to design, literature review, analysis, revision and approval of the final version.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Christopher Koh, FAASLD,FACP,MD, Attending Doctor, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9B-16, MSC 1800, Bethesda, MD 20892, United States. christopher.koh@nih.gov
Telephone: +1-301-4356121 Fax: +1-301-4020491
Received: May 21, 2019
Peer-review started: May 21, 2019
First decision: June 9, 2019
Revised: July 3, 2019
Accepted: July 19, 2019
Article in press: July 19, 2019
Published online: August 28, 2019
Peer-review started: May 21, 2019
First decision: June 9, 2019
Revised: July 3, 2019
Accepted: July 19, 2019
Article in press: July 19, 2019
Published online: August 28, 2019
Core Tip
Core tip: Delta hepatitis is a progressive disease affecting millions worldwide. Current treatment options have limited efficacy. This review focuses on the history of interferon therapy, novel therapies that have been developed and future treatment options for a possible functional cure.